Psilocybin-Research.com Research. Clarity. Progress.
Preparing publication tracker
Psilocybin-Research.com Research. Clarity. Progress.

Psilocybin Research Publication Tracker

Search, analyze, export, and monitor psilocybin and psilocin literature across peer-reviewed papers, preprints, reviews, protocols, and clinical trials.

Database up to date Last update: Jul 2, 2026 23:06 UTC
Database evidence 3,974 indexed records
Indexed records 3,974 SQLite literature index
Published 3,210 Peer-reviewed / formal records
Preprints 477 Marked as not peer reviewed
Clinical trials 287 ClinicalTrials.gov records
Source coverage 8 active sources
Source Count Share Status
Europe PMC 2,553 64.2% Active
PubMed 302 7.6% Active
ClinicalTrials.gov 287 7.2% Active
OpenAlex 283 7.1% Active
PsyArXiv 216 5.4% Active
Crossref 157 4% Active
bioRxiv 142 3.6% Active
Publication timeline 3,071 dated records
3,071 records since 2020
Annual records Cumulative line
3,974Total Publications
3,833Psilocybin Records
553Psilocin Records
Search Matches
388Journals
66Research Topics
Current display No search or filter specified Showing the latest indexed records until a keyword search is submitted.
Page 8 of 199

Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: A randomised [18F]FDG-PET study.

Classical psychedelics such as N,N-dimethyltryptamine (DMT) modulate consciousness via serotonergic receptor agonism, and are increasingly investigated for their psychotherapeutic potential. When combined with the monoamine oxidase A (MAO-A) inhibitor harmine-mimicking the pharmacological profile of ayahuasca-oral DMT induces a psychedelic experience lasting...

Unknown journal 2026-05-31 Egger K, Bozsak R, Aicher HD, Sari H, Poetzsch SN, Rominger A, Martin-Soelch C, Smallridge JW, Dornbierer D, Quednow BB, Scheidegger M, Cumming P.
Europe PMC Published psilocybin Brain ImagingPharmacologyReceptor PharmacologyConsciousnessAgingClinical TrialHealthy Volunteers Clinical Trial

Psilocybin Decreases Preference for Large Rewards Accompanied by Increased Activity of Parvalbumin Neurons With Perineuronal Nets in the Medial Prefrontal Cortex.

Clinical trials suggest that a single dose of psilocybin may be an effective treatment for substance use disorders. Choice impulsivity is a value-based decision-making bias that predicts drug-intake escalation and is commonly associated with substance use disorders. The dorsomedial prefrontal cortex regulates choice impulsivity and is enriched with 5-HT2A re...

Unknown journal 2026-05-31 Houff J, Williams A, Allen O, Gisabella B, Pantazopoulos H, Del Arco A.
Europe PMC Published psilocybin AddictionReceptor PharmacologyBiomarkersClinical Trial Clinical Trial Prefrontal CortexNeurons

Reorganization of Human Brain Waves Across Diverse States of Consciousness

Brain waves are ubiquitous phenomena of human brain activity. As they propagate, they coordinate neural communication, shaping conscious perception. Understanding how brain waves unfold across space and time is thus critical for uncovering the neural mechanisms that support and suppress consciousness. Here, we analyzed data from the Human Connectome Project ...

bioRxiv 2026-05-31 Fotiadis P, Jang H, Dai R, Li D, Cofré R, Timmermann C, Mashour GA, Hudetz AG, Huang Z.
bioRxiv PREPRINT (not peer reviewed) psilocybin Mechanism of ActionConsciousness Other

Hallucinogen-Assisted Psychotherapy for Trauma Disorders: A Bionian Lens.

There has been an increasing interest in the use of classic psychedelics (such as psilocybin) and 3,4-methylenedioxymethamphetamine (MDMA) for treating mental health conditions. Individuals often describe psychedelic sessions as among the most significant experiences in their lives, emphasizing the sense of awe, connectedness, and spiritual transformation ta...

Unknown journal 2026-05-31 Miller CWT, Kozak Z.
Europe PMC Published psilocybin DepressionAnxietyAddictionMechanism of ActionSpirituality Other HumansN-Methyl-3

Expectations and Motivations for Participation in Clinical Trials Utilizing Psychedelics for Treatment-Resistant Depression: A Qualitative Study.

PurposeExpectations strongly shape participant experiences in clinical trials, contributing to placebo effects that complicate interpretation of outcomes. While quantitative tools exist to measure expectations, their subjective and multidimensional nature, especially for individuals with treatment-resistant depression (TRD), remains underexplored. This study...

Unknown journal 2026-05-31 Poppe C, Lyck L, Bechtold L, Repantis D.
Europe PMC Published psilocybin DepressionMechanism of ActionClinical TrialTreatment-Resistant Depression Clinical Trial HumansHallucinogens

Psychedelic Therapy and the Role of Music: A Scoping Review of Quantitative Evidence on Subjective and Objective Outcomes.

PurposePsychedelics have received considerable attention due to their potential in treating psychiatric disorders. The "setting" during psychedelic-assisted therapy (PAT) is recognized as playing a central role in the experience, during which music features prominently. Although music is theorized as directing and shaping psychedelic sessions, its precise co...

Unknown journal 2026-05-31 Rowe T, Hurzeler T, Towers E, Louie E, Morley KC.
Europe PMC Published psilocybin Mechanism of ActionEmotional ProcessingSystematic ReviewReview ArticleDrug Interactions Systematic Review HumansLysergic Acid Diethylamide

Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.

Classical serotonergic psychedelics, such as psilocybin, show emerging evidence of therapeutic potential across a range of mental health disorders, including depression, anxiety, and substance use disorders, with indications of transdiagnostic efficacy. While early-phase studies yielded encouraging results, recent larger-scale phase 3 trials, such as those e...

Unknown journal 2026-05-31 Kelly JR, Sheridan C, Iusan P, Coakley L, Burke L, Brennan C, MacDonald A, Ivers JH, Trepel D, Tormey G, Finnegan M, Young GW, Harkin A.
Europe PMC Published psilocybin DepressionAnxietyAddictionMechanism of ActionAgingClinical TrialTreatment-Resistant Depression Clinical Trial HumansHallucinogens

Studies on enzymatic hydrolysis of psilocin-O-glucuronide for screening of psilocin in human urine by liquid chromatography-triple quadrupole tandem mass spectrometry.

Psilocin is a psychedelic indole alkaloid and one of the major human metabolites of its phosphorylated precursor, psilocybin. Psilocin binds to the serotonin receptor, 5-HT2A, and dose-dependently induces hallucinogenic effects stronger than psilocybin. As a result, psilocin has been a drug of interest in the analytical toxicology community for years. In viv...

Unknown journal 2026-05-31 Barajas DA, Carter HCN, Tomedi MR, Lam HY, Deloatch TN, Reynolds GD, Castaneto MS, Ke P.
Europe PMC Published psilocybinpsilocin Receptor PharmacologyToxicity Other HumansGlucuronides

Classic psychedelics and personality: An updated systematic review.

BackgroundThe impact of classic psychedelics (5-HT2A receptor agonists) on personality traits has been studied for decades, and it has been hypothesized that the mechanisms underlying these changes are linked to agonism at cortical serotonergic 5-HT2A receptors. However, research results are contradictory. Therefore, the present paper aims to systematically ...

Unknown journal 2026-05-30 Vicentini AB, de Paula CC, Silva Reis JA, Bouso JC, Hallak JEC, Dos Santos RG.
Europe PMC Published psilocybin Mechanism of ActionReceptor PharmacologyMicrodosingPersonality ChangeRandomized Controlled TrialSystematic ReviewReview ArticleObservational Study Randomized Controlled Trial

A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incur...

ClinicalTrials.gov 2026-05-28 University of Washington
ClinicalTrials.gov CLINICAL TRIAL psilocybin DepressionAnxietyClinical TrialObservational StudyCancer PatientsSafetyAdverse Events Clinical Trial AnxietyDepression

Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis

Abstract Background and Aims Psilocybin-assisted psychotherapy (PAP) is a novel, transdiagnostic treatment in which the 5-HT2A receptor agonist psilocybin is combined with psychotherapy. Studies to date have evaluated PAP's effects on depression, substance use, and end-of-life adjustment. Relatively less attention has been given to its effects on anxiety sym...

Journal of Psychedelic Studies 2026-05-28 Hood Alex, Elkins Gary
Crossref Published psilocybin DepressionAnxietyAddictionEnd-of-Life DistressReceptor PharmacologyMeta-AnalysisSystematic ReviewReview Article Meta-Analysis

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.

IntroductionDespite renewed investigations into classical psychedelic compounds, their pharmacokinetic profiles remain incompletely understood.MethodsThis systematic review collated data from healthy adult volunteers on the pharmacokinetic properties of lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), mescaline, and 5-methoxy-N,N-dimet...

Unknown journal 2026-05-28 Hampsey E, Martin K, Kalfas M, Benson L, Wihlborg S, Jelen L, Young AH, Rucker J.
Europe PMC Published psilocybin PharmacologySystematic ReviewReview Article Systematic Review

Effects of psilocybin on sleep quality and brain microstructure in chronic cluster headache.

BackgroundPatients with chronic cluster headache (CCH) suffer from poor sleep, which may impact their brain microstructure and parenchymal clearance of waste products. Psilocybin has shown promise for the treatment of CCH and has been linked to increased neuroplasticity with possible influences on brain microstructure.AimsTo investigate the effects of psiloc...

Unknown journal 2026-05-28 Brendstrup-Brix K, Ozenne B, Fisher PM, Stenbæk DS, Petersen AS, Armand S, McCulloch DE, Marstrand-Joergensen MR, Ulv Larsen SM, Johansen A, Jensen RH, Knudsen GM, Madsen MK.
Europe PMC Published psilocybin Headache / MigraineNeuroplasticityReceptor Pharmacology Other

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.

Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transiti...

Unknown journal 2026-05-28 Eskinazi M, Nasserdine R, Cusin RM, Baniotoupoulos P, Saccaro LF, De Pieri M, Corino T, Seragnoli F, Briefer JF, Aboulafia Brakha T, Richard-Lepouriel H, Penzenstadler L, Böge K, Kirchner M, Zullino D, Højlund M, Sapienza J, Bosia M, Catalan A, Vieta E, Solmi M, Sabé M.
Europe PMC Published psilocybin DepressionAddictionMeta-AnalysisSystematic ReviewReview ArticleObservational StudySafety Meta-Analysis

Rapid and Sensitive Detection of Psilocybin and Psilocin in Urine by Surface-Enhanced Raman Spectroscopy

ABSTRACT Psilocybin, one of the primary active compounds in magic mushrooms, is metabolized into psilocin in the human body. In this study, we employed surface-enhanced Raman spectroscopy (SERS), leveraging its unique molecular fingerprinting capabilities and high sensitivity, in combination with silver-coated gold nanoparticles (Au@AgNPs) as the enhancement...

Journal of Raman Spectroscopy 2026-05-27 Lin Wei, Chen Hong, Li Yuanyuan
Crossref Published psilocybinpsilocin AgingToxicity Other

Psilocybin-induced neurocardiogenic syncope: a case report.

BackgroundPsilocybin is among the serotonergic psychedelics closest to potential FDA approval, with growing evidence of therapeutic benefit across psychiatric conditions. As clinical trials expand, systematic characterization of adverse events (AEs) remains essential. While transient hypertensive responses are well documented, hypotensive events such as neur...

Unknown journal 2026-05-27 Atiq MA, Weisman E, Guerra RB, Martinez LL, Yaden DB, Barrett FS, Nayak S, Sayali C.
Europe PMC Published psilocybin AnxietyBrain ImagingConsciousnessAgingEmotional ProcessingClinical TrialCase ReportSafetyAdverse Events Clinical Trial

Blinding integrity in psychedelic research: Evidence from a comparative randomized controlled trial of psilocybin, MDMA, and methylphenidate in healthy volunteers.

Maintaining effective blinding is a major methodological challenge in psychedelic research. This study provides a comprehensive evaluation of blinding integrity in 120 healthy volunteers who received either psilocybin, MDMA, or methylphenidate (active placebo) in a double-blind, randomized controlled trial. Using a multi-level assessment incorporating forced...

Unknown journal 2026-05-27 Belinger L, Rieser NM, Engeli EJE, Becciolini L, Clamote M, Pribis M, Saissi F, Florineth GA, Hehl NL, Herdener M, Preller KH.
Europe PMC Published psilocybin Randomized Controlled TrialHealthy Volunteers Randomized Controlled Trial

Retail Availability of Intoxicating Cannabis and Mushroom Products Across Eleven U.S. Cities: Sales Persist Despite Prohibitions.

ObjectiveRetail sales of intoxicants, including derived intoxicating cannabis products (DICPs) such as delta-8 tetrahydrocannabinol (THC) and hallucinogenic mushrooms, have rapidly increased throughout the US, despite their sale being federally illegal. This study assessed DICP and hallucinogenic mushroom availability in US smoke shops with differing DICP an...

Unknown journal 2026-05-27 LoParco CR, Rossheim ME, Tillett KK, Cui Y, Johnson M, Speer M, Mihelich D, Amdeta H, Ndisebuye D, Berg CJ.
Europe PMC Published psilocybin General Other

Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: a case report.

BackgroundAdvanced Alzheimer's disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter large-scale brain network dynamics and to induce plasticity-related mechanisms in preclinical models, yet clinical data in advanced dementia remain lacking.Case presentationWe report the case of an octogena...

Unknown journal 2026-05-27 Lago M, Cerveira M, Simonet JX.
Europe PMC Published psilocybin NeuroplasticityMechanism of ActionEmotional ProcessingCase ReportAnimal StudyDrug Interactions Clinical Trial

Live source coverage

3,974 indexed records across 8 active sources.

3,210Published
477Preprints
287Clinical trials
  1. Europe PMC 2,553 records · 64.2%
  2. PubMed 302 records · 7.6%
  3. ClinicalTrials.gov 287 records · 7.2%
  4. OpenAlex 283 records · 7.1%
  5. PsyArXiv 216 records · 5.4%
  6. Crossref 157 records · 4%
  7. bioRxiv 142 records · 3.6%
  8. medRxiv 34 records · 0.9%

Counts exclude hidden records and curated false positives. Preprints remain labeled as not peer reviewed in search results and exports.